Oncology is one of the fastest growing segments of drug development and, given the needs of cancer suffers that aren't met, that's good news. It's also good business. Cancer-fighting drugs did an estimated $75 billion in global sales last year.
With that in mind, this episode of The Motley Fool's Market Checkup tackles the biggest news stories of the week involving cancer drugs, and the companies that make them. Watch and find out the latest on a potential biotech buyout, and which big pharma stock got a surprising result in late-stage trials.
In this video, health-care analysts David Williamson and Max Macaluso bring viewers up to date with the latest Onyx Pharmaceuticals (UNKNOWN:UNKNOWN) vs. Amgen (NASDAQ:AMGN) buyout drama, and whether some of the big pharmas sniffing around Onyx's cancer fighting drug portfolio would be a better strategic fit.
Follow David on Twitter: @MotleyDavid.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.